The molecular glues pipeline and clinical trial analysis
report delivers important insights on ongoing research, clinical
strategies, upcoming therapeutics, and commercial
analysis.
LAS VEGAS, July 11, 2024 /PRNewswire/ -- DelveInsight's
'Molecular Glues Competitive Landscape –
2024' report provides comprehensive global coverage
of available, marketed, and pipeline molecular glues in various
stages of clinical development, major pharmaceutical companies
working to advance the pipeline space, company assessment,
comparative assessment, and future growth potential of the
molecular glues competitive domain.
Key Takeaways from the Molecular Glues Competitive Landscape
Report
- Over 10+ companies are evaluating 12+ molecular
glues in various stages of development, and their anticipated
acceptance in the oncology market would significantly increase
market revenue.
- Key molecular glues companies such as Bristol Myers Squibb, Monte Rosa Therapeutics Inc.,
Revolution Medicines Inc., Nurix Therapeutics, Nested Therapeutics,
DeuteRx, and others are evaluating new molecular glues to
improve the treatment landscape.
- Promising molecular glues such as Mezigdomide, Golcadomide,
Iberdomide, MRT-2359, RMC 6291, NX-2127, NST-628, SP-3164, and
others are under different phases of molecular glues clinical
trials.
- In May 2024, Takeda
Pharmaceuticals announced an exclusive licensing deal with
China-based Degron Therapeutics to
develop novel molecular glue degraders for various oncology,
neuroscience, and inflammatory disease targets.
- In May 2024, NEOsphere
Biotechnologies GmbH announced a collaboration with Kymera
Therapeutics, Inc. focused on unlocking undrugged or poorly drugged
disease-causing protein targets that can be only or best addressed
by Targeted Protein Degradation. Under the agreement, NEOsphere
Biotechnologies will utilize its target- and E3-agnostic platform
to screen molecular glue compounds on a proteome-wide level and in
a native context.
- In March 2024, Nurix
Therapeutics, Inc. announced that the FDA had lifted the
partial clinical hold on the U.S. Phase Ia/Ib study evaluating
NX-2127 in adults with relapsed/refractory B-cell malignancies. The
partial clinical hold on the study was announced by Nurix on
November 1, 2023, following the
company's communication to the FDA of its intention to transition
to an improved manufacturing process.
- In November 2023, Kymera
Therapeutics shared promising results from the Phase I clinical
trial of its lead program, KT-474, marking a significant milestone
in the field of targeted protein degradation (TPD).
- In September 2023, Orionis
Biosciences, a privately held life sciences company with an
integrated drug discovery and chemical biology platform, announced
a multi-year collaboration with Genentech, a member of the Roche
Group, to discover novel small molecule medicines for challenging
targets in major disease areas, including oncology and
neurodegeneration. Under the terms of the agreement, Orionis will
be responsible for the discovery and optimization of molecular
glues for Genentech's designated targets, while Genentech will be
responsible for subsequent later-stage preclinical, clinical
development, regulatory filing, and commercialization of such small
molecules.
Request a sample and discover the recent advances in molecular
glues treatment @ Molecular Glues Competitive Landscape
Report
Molecular Glues Overview
Molecular glues are a novel class of small molecules that
facilitate the interaction between proteins, leading to the
degradation or modulation of target proteins that are typically
difficult to drug. Unlike traditional inhibitors that block active
sites of enzymes, molecular glues work by binding to two different
proteins, often an E3 ubiquitin ligase and a target protein,
bringing them into close proximity. This interaction results in the
ubiquitination and subsequent proteasomal degradation of the target
protein. The mechanism offers a unique therapeutic approach,
particularly in oncology, where it can selectively degrade proteins
essential for cancer cell survival. The specificity and efficacy of
molecular glues have shown promise in preclinical and clinical
studies, indicating their potential to address previously
"undruggable" targets.
The discovery and development of molecular glues involve
sophisticated techniques in chemical biology and proteomics.
Researchers use high-throughput screening and structure-based drug
design to identify compounds that can act as molecular glues. One
of the most well-known examples is thalidomide and its derivatives,
which act as molecular glue by promoting the degradation of
specific transcription factors. The field is rapidly evolving, with
ongoing research aimed at expanding the repertoire of targetable
proteins and improving the specificity and potency of these
compounds. As our understanding of protein-protein interactions and
the ubiquitin-proteasome system deepens, molecular glues are poised
to become a transformative modality in the treatment of various
diseases.
Find out more about molecular glues @ Molecular Glues
Treatment
Molecular Glues Pipeline Analysis: Drug Profile
Golcadomide : Bristol Myers
Squibb
Golcadomide (CC-99282) is an oral molecular glue that promotes
degradation of IKZF1/3 transcription factors (Ikaros/Aiolos) by
engaging the cereblon E3 ubiquitin ligase complex. Structurally
golcadomide is a novel thalidomide analogue (known as a
CELMoD/cereblon E3 ligase modulator). It has immunomodulatory
actions, with enhanced antiproliferative and proapoptotic
activities. Currently, Golcadomide is in Phase III stage of
development for the treatment of B-cell Lymphoma.
RMC 6291: Revolution Medicines, Inc.
RMC-6291 is an orally active, covalent inhibitor targeting KRAS
G12C(ON). It forms a tri-complex in tumor cells between KRAS
G12C(ON) and cyclophilin A (CypA), thereby preventing KRAS G12C(ON)
from signaling through steric hindrance of RAS effector binding.
This inhibition blocks ERK signaling and induces apoptosis in KRAS
G12C-mutant H358 cells. Additionally, RMC-6291 effectively inhibits
the proliferation of KRAS G12C mutant cells, with a median IC50 of
0.11 nM. Currently, RMC-6291 is in Phase I/II stage of development
for the treatment of Solid tumors including NSCLC and SCLC.
NST-628: Nested Therapeutics
NST-628 is a fully brain-penetrant, mechanistically novel
non-degrading molecular glue that targets multiple nodes in the
RAS/MAPK pathway. NST-628 was developed based on Nested's
proprietary structural insights of how signaling complexes form and
function in cancer and addresses common pitfalls of other
MAPK-targeted compounds, which remain unable to circumvent the risk
of resistance via signaling pathway reactivation. It is currently
being evaluated in Phase I for the treatment of Solid tumors.
A snapshot of the Molecular Glues Pipeline Drugs mentioned in
the report:
Molecular
Glues
|
Company
|
Phase
|
Indication
|
MoA
|
Mezigdomide
|
Bristol Myers
Squibb
|
Phase III
|
Multiple
myeloma
|
Apoptosis stimulants;
CRBN protein modulators; Ubiquitin protein ligase
modulators
|
Golcadomide
|
Bristol Myers
Squibb
|
Phase III
|
Lymphoma
|
CRBN protein
modulators; Ubiquitin protein ligase modulators
|
Iberdomide
|
Bristol Myers
Squibb
|
Phase III
|
Multiple
Myeloma
|
Ubiquitin protein
ligase complex modulators
|
MRT-2359
|
Monte Rosa
Therapeutics, Inc
|
Phase I/II
|
Solid tumors
|
Peptide-chain-release
factor 3 degraders
|
RMC 6291
|
Revolution Medicines,
Inc.
|
Phase I/II
|
Solid tumors
|
KRAS protein
inhibitors
|
NX-2127
|
Nurix
Therapeutics
|
Phase I
|
B-cell
malignancies
|
Agammaglobulinaemia
tyrosine kinase degraders; Agammaglobulinaemia tyrosine kinase
inhibitors; IKZF1 protein degraders; IKZF3 protein
degraders
|
NST-628
|
Nested
Therapeutics
|
Phase I
|
Solid tumors
|
Mitogen-activated
protein kinase inhibitors; Ras protein modulators
|
SP-3164
|
DeuteRx
|
Phase I
|
Non-Hodgkin's
Lymphoma
|
CRBN protein
modulators; IKZF1 protein degraders; IKZF3 protein
degraders
|
Learn more about the emerging molecular glues @ Molecular
Glues Clinical Trials
Scope of the Molecular Glues Competitive Landscape
Report
- Coverage: Global
- Key Molecular Glues Companies: Bristol Myers Squibb,
Monte Rosa Therapeutics Inc., Revolution Medicines Inc., Nurix
Therapeutics, Nested Therapeutics, DeuteRx, and others
- Key Pipeline Molecular Glues: Mezigdomide, Golcadomide,
Iberdomide, MRT-2359, RMC 6291, NX-2127, NST-628, SP-3164, and
others
- Company Analysis, Therapeutic Assessment, Pipeline
Assessment, Inactive drugs assessment, Unmet Needs
Dive deep into rich insights for new molecular glues,
visit @ Molecular Glues
Table of Contents
1.
|
Molecular Glues
Pipeline Report Introduction
|
2.
|
Molecular Glues
Pipeline Report Executive Summary
|
3.
|
Molecular Glues
Pipeline: Overview
|
4.
|
Molecular Glues
Marketed Drugs
|
4.1.
|
REVLIMID: Bristol Myers
Squibb
|
5.
|
Molecular Glues
Clinical Trial Therapeutics
|
6.
|
Molecular Glues
Pipeline: Late-Stage Products (Pre-registration)
|
7.
|
Molecular Glues
Pipeline: Late-Stage Products (Phase III)
|
8.
|
Molecular Glues
Pipeline: Mid-Stage Products (Phase II)
|
8.1.
|
Drug Name: Company
Name
|
9.
|
Molecular Glues
Pipeline: Early-Stage Products (Phase I)
|
9.1.
|
NST-628: Nested
Therapeutics
|
10.
|
Molecular Glues
Pipeline Therapeutics Assessment
|
11.
|
Inactive Products in
the Molecular Glues Pipeline
|
12.
|
Company-University
Collaborations (Licensing/Partnering) Analysis
|
13.
|
Unmet Needs
|
14.
|
Molecular Glues Market
Drivers and Barriers
|
15.
|
Appendix
|
Related Reports
Atopic Dermatitis Market
Atopic Dermatitis Market Insights, Epidemiology, and Market
Forecast – 2034 report deliver an in-depth understanding of the
disease, historical and forecasted epidemiology, as well as the
market trends, market drivers, market barriers, and key gene
therapy In atopic dermatitis companies, including Arcutis
Biotherapeutics, Amgen, Kyowa Kirin, Dermavant Sciences, Cara
Therapeutics, Pfizer, Arena Pharmaceuticals, BioMimetix, Eli Lilly
and Company, Aldeyra Therapeutics, Inc., Hangzhou Yirui
Pharmaceutical Technology Co., Ltd, LEO Pharma, Corvus
Pharmaceuticals, Inc., Brexogen Inc., Sanofi, Shaperon, UCB Pharma,
Q32 Bio Inc., Akeso, Apogee Therapeutics, Inc., Allakos Inc.,
Biosion, Inc., among others.
Non-small Cell Lung Cancer Market
Non-small Cell Lung Cancer Market Insights, Epidemiology, and
Market Forecast – 2032 report delivers an in-depth
understanding of the disease, historical and forecasted
epidemiology, as well as the market trends, market drivers, market
barriers, and key NSCLC companies, including EMD Serono, Merck,
Cellular Biomedicine Group, Inc., Celgene, CellSight Technologies,
Inc., BeyondSpring Pharmaceuticals Inc., J Ints Bio, Forward
Pharmaceuticals Co., Ltd., AstraZeneca, Bristol-Myers Squibb,
Teligene US, Rain Oncology Inc, ReHeva Biosciences, Inc., Amgen,
Novartis, RedCloud Bio, Parexel, Vitrac Therapeutics, LLC, Mythic
Therapeutics, Instil Bio, Mirati Therapeutics Inc., Daiichi Sankyo,
Inc., AstraZeneca, Precision Biologics, Inc, Promontory
Therapeutics Inc., Palobiofarma SL, Regeneron Pharmaceuticals,
Revolution Medicines, Inc., Cullinan Oncology, LLC, Iovance
Biotherapeutics, Inc., Innate Phar, among others.
Colorectal Cancer Market
Colorectal Cancer Market Insights, Epidemiology, and Market
Forecast – 2032 report delivers an in-depth understanding of
the disease, historical and forecasted epidemiology, as well as the
market trends, market drivers, market barriers, and key colorectal
cancer companies, including Mirati Therapeutics, Merck,
Hutchison Medipharma, EpicentRx, Eli Lilly, Amgen, Daiichi Sankyo,
AstraZeneca, Cardiff Oncology, NeoImmuneTech, among others.
Multiple Myeloma Market
Multiple Myeloma Market Insights, Epidemiology, and Market
Forecast – 2034 report delivers an in-depth understanding of
the disease, historical and forecasted epidemiology, as well as the
market trends, market drivers, market barriers, and key multiple
myeloma companies, including Johnson & Johnson (Janssen), Pfizer, AbbVie and Roche
(Genentech), Regeneron Pharmaceuticals, Bristol-Myers Squibb,
Celgene, Roche (Genentech), Arcellx, Novartis, Regeneron
Pharmaceuticals, BeiGene, CARsgen Therapeutics, Cartesian
Therapeutics, C4 Therapeutics, Heidelberg Pharma, Bristol-Myers
Squibb, RAPA Therapeutics, AbbVie (TeneoOne), Takeda,
among others.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market
Research firm focused exclusively on life sciences. It supports
pharma companies by providing comprehensive end-to-end solutions to
improve their performance.
Contact Us
Shruti
Thakur
info@delveinsight.com
+91-9650213330
www.delveinsight.com
Logo:
https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/molecular-glues-clinical-trial-pipeline-appears-robust-with-10-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-302194519.html